Chairman of Avia Solutions Group Gediminas Ziemelis: The challenges of factory freighters compared to P2F

DUBLIN, Ireland, July 27, 2023 (GLOBE NEWSWIRE) — The pandemic years brought record revenues from air cargo. With supply limited due to the grounding of passenger planes, and demand up thanks to booming ecommerce, prices per cargo kilogram soared. According to TAC Yields figures from the Trade and Transport Group, in 2019 air cargo from Hong Kong to North America cost $3.80/kg while the price from Europe to North America was $2.10/kg. By 2022, these same services cost $9.00/kg and $4.50/kg respectively.

Unsurprisingly, this situation transformed the position of air cargo providers. Cargo revenue more than doubled from $100 billion in 2019 up to $210 in 2021 (these are the IATA’s figures) while passenger revenue plummeted from $607 billion annually down to $239 billion. Cargolux’s annual revenue grew from $2.2 billion to $5.1 billion over the course of the pandemic, and Silkway more than doubled its revenue and saw its margin transform from -10% to +30%. These huge gains, plus the long-term potential of ecommerce (which has led Airbus and Boeing to make optimistic forecasts for growth in air cargo), led many airlines to focus more on cargo.

However, increased belly capacity has led cargo prices to drop steeply once more. The IATA forecasts that year-on-year cargo yield will fall by 28.6% this year. This means air cargo, a notoriously cyclical sector, is once again entering a period of turbulence. This is the context in which airlines are deciding whether to purchase new freight planes.

New freighters vs passenger-to-freighter conversions

Airlines and air cargo providers are pursuing different strategies when it comes to building up their freighter fleets. According to KPMG’s latest report, last year, 35 orders were made for new 777-200F aircraft, 33 were made for new 777-8Fs, and 20 providers bought new A350Fs. These orders were made by both dedicated air cargo providers (Cargolux, Silkway West, DHL, FedEx) and airlines (Lufthansa Cargo, Qatar, Air Canada, China Airlines, EVA, Air France, Etihad, SIA and Western Global). Meanwhile, annual passenger-to-freighter (P-to-F) conversions have reached historic highs with volume estimated to peak at 180 per year by 2025, and then settle at around 160 aircraft per year. This compares to 70 units per year before the COVID-19 pandemic.

A number of factors are affecting the choice of purchasing either new freighters or P-to-F conversions. Naturally, cost is a major one, taking into account variables like total order number, fuel burn and maintenance as well as the upfront production costs. Production lead times is another key factor, as is cargo volume and flexibility.

Factor 1: Leasing Costs

There is a massive difference in the baseline costs for new versus converter freighters. The upfront price for a brand new 777-200F or A350F is roughly $170 to $185 million, or a monthly lease rate of between $1.2 and $1.3 million. Looking at the order book of those who made purchases last year, the majority of these airlines have a significant amount of these types of aircraft in their fleet, particularly the combination carriers. In these cases, it is highly likely that the actual purchase cost was much lower than the $170 to $185 million range. Positive economies of scale will also be a factor in keeping costs down for these airlines. Nevertheless, despite these savings they will still be looking at monthly lease rates of $1 million.

By contrast, leasing a 777-300 P-to-F conversion will cost $0.6 million per month, or roughly $65 million to purchase outright. This aircraft is likely to compare well with its production rivals, but at a fraction of the cost.

Factor 2: MRO and operating costs

Airlines will make savings on P-to-Fs when it comes to MRO. With access to the second hand market for parts, maintaining these aircraft will be considerably less expensive than keeping new planes in operation.

Naturally, alongside cost savings, access to second hand parts can also accelerate and simplify the maintenance process for airlines.

Fuel burn is another consideration. Historically, we have seen significant improvements in fuel burn when new aircraft come online. When the 777F was introduced as a replacement to the 747-400F, its 6,800 kg/h fuel burn was a huge improvement on the 10,230 kg/h offered by the 747-400F. However, with the new 777X and A350 we are unlikely to see improvements in fuel burn to match the 30% reduction seen from the 747-400F to the 777F. A 10% to 15% change is the most we can realistically expect.

On balance, while improved fuel burn and (in some cases) economies of scale may be able to soften the financial blow of purchasing a new freighter, in terms of costs P-to-F conversions are a far more attractive option.

Factor 3: Delivery volume and flexibility

New freighter aircraft have the potential to offer benefits in terms of delivery capacity and flexibility. Nose loading in particular offers a huge advantage. It enables aircraft to deliver outsized cargo such as large generators, engines, trucks and specialized technology. Crucially, this outsized cargo is lucrative, offering higher profitability than normal pallet deliveries.

However, new freighters being produced such as the 777X and the A350F do not offer nose loading. This levels the playing field in terms of the advantages a dedicated freighter has over a conversion, as both are now restricted to cargo that can fit through the side doors.

How do conversions fare in terms of volume, packing density and gross payload? Let’s consider the 777-300ERCF compared to the 777F (which currently makes up half of the world’s large freighter fleet) using data from a 2022 comparison by Aircraft Commerce.

While the 777F offers a larger overall payload of 106.6 metric tonnes, in terms of volume the 777-300ERCF comfortably outperforms the 777F. The 777-300ERCF offers almost 6,000 cu ft. more in total volume than the 777F (28,739 cu ft. compared to 22,971). Revenue per payload is also considerably higher. At 6.5lbs, it is 186,804 cu ft. and at 7.5lbs it is 190,900 cu ft, which compares to the 777F’s 149,312 cu ft. and 172,283 cu ft. respectively. One important point to note with this comparison is that it is volume, not gross payload, that matters most in ecommerce express operations, which are likely to be an important growth driver in the future. And in this area, the 777-300ERCF offers a clear advantage.

Avoiding the trap of new freighter purchases

Airbus estimates that an additional 1,040 freighters will need to be added to the global cargo fleet by 2041 – Boeing’s forecasts are even more confident. Buying new cargo freighters to meet this need carries significant risk for airlines. With cargo prices having fallen significantly, the CAPEX investment in a new A350 or 777F represents a massive financial outlay at a time when prices are falling fast. Investing heavily in a new $185-million freighter might have made sense in 2021 when air cargo prices were at record levels. However, in 2023 this is no longer a prudent policy.

Furthermore, there is little to be gained in performance and capacity from purchasing a new freighter. P-to-F conversions are capable of matching new production freighters in terms of volume, and they have notable advantages when it comes to maintenance and production.

Ultimately, conversions represent a much lower financial risk, enabling airlines to sustainably ramp up their air cargo capacity. That is why we are seeing significant growth in P-to-F conversions, while the delivery of new freight aircraft has stagnated. Quite rightly, many airlines are not willing to take on the financial risk of a new aircraft as prices tumble, and see little upside compared to refurbished passenger planes.

About Gediminas Ziemelis

Gediminas Ziemelis (born April 4, 1977) is an accomplished Lithuanian entrepreneur, business consultant, and the founder and current Chairman of the Board of Avia Solutions Group, one of the largest global ACMI (Aircraft, Crew, Maintenance, and Insurance) provider, operating a fleet of 180 aircraft. He was selected twice among the top 40 most talented young industry leaders by Aviation Week & Space Technology.

Gediminas is known for his cosmopolitan mindset and exceptional management skills, which have contributed to his success in various business fields. Over his 26-year-long career, Gediminas has founded more than 100 start-ups, 50% of which are still in operation, led companies through 4 successful IPO/SPO processes, and raised over 800 million euros in global public capital and bond markets.

In December 2022, Gediminas Ziemelis was listed as the richest Lithuanian by TOP Magazine, with estimated assets worth 1.68 billion euros.

Gediminas is the largest donator of Rimantas Kaukenas Support Group, a charity and support fund, that provides help to children with oncological diseases and their families. He is also the biggest shareholder in the leading basketball club Wolves.

Media contact: 
Silvija Jakiene 
Chief Communications Officer 
Avia Solutions Group 
silvija.jakiene@aviasg.com 
+370 671 22697

GlobeNewswire Distribution ID 1000831891

Wistar-Led Team Awarded More Than $12 Million Grant from the NCI to Investigate Link Between Epstein-Barr Virus and Carcinomas

PHILADELPHIA, PA, July 26, 2023 (GLOBE NEWSWIRE) — It’s been known since the 1960s that Epstein-Barr Virus (EBV) causes a variety of cancers, but research has overwhelmingly focused on its connection to lymphomas. Now, a multidisciplinary team of scientists led by The Wistar Institute has been awarded a more than $12 million National Cancer Institute (NCI) Program Project Grant (P01), a highly competitive five-year grant that includes a crosssection of researchers from various disciplines and institutions throughout the country. The multidisciplinary team led by Wistar scientists is exploring the role of Epstein-Barr Virus in epithelial cancers. Epithethelial cells form functional structures in organ tissue throughout the human body; they are often the site for solid organ cancers, including the most common cancers, which are known as carcinomas.

The new research will focus on basic questions about how EBV infection of normal epithelial cells transforms them into cancer-cells. Scientists also intend to build on this research to identify better and more selective therapeutic targets.

“We are investigating unexplored aspects of EBV and malignancies, potentially uncovering unique characteristics or pathways that can be targeted for therapeutic intervention,” said Italo Tempera, Ph.D., associate professor of the Gene Expression & Regulation Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute. “This fresh perspective could lead to groundbreaking discoveries and innovative treatment strategies for EBV and epithelial malignancies.”

The project brings together scientists from The Wistar Institute and Harvard University, including experts in epigenetics, metabolomics and drug discovery. It’s the first time researchers from this variety of disciplines have combined their efforts to focus entirely on the EBV-epithelial cancer link.

“We’ve put together a new strategy, a new way of attacking the problem,” said Paul Lieberman, Ph.D., Hilary Koprowski, M.D., Endowed Professor and director of the Center for Chemical Biology and Translational Medicine at Wistar. “By working together across different modalities, there’s an opportunity for each of us to learn from the synergy and expertise of the other investigators.”

EBV is one of the most common human viruses, infecting an estimated 95% of people by the time they reach adulthood. Symptoms are usually mild, and most people recover within a few weeks. However, the virus can remain latent in the human body for years or even decades, and it causes some people to develop cancer later in life.

While research has historically focused on lymphomas, EBV-linked epithelial cancers are both more common and more deadly. Epithelial cancers represent 75% of the 200,000 EBV-related cancer cases diagnosed each year, and these cancers also have higher mortality rates and treatment failures.

“This grant put together a team that is now focused on this type of cancer that has been neglected, even though it’s the most common form of EBV cancers,” Lieberman said. The grant will fund three main research projects. The first will look at how EBV establishes a long-term infection within epithelial cells. The second will study how it causes genetic and metabolic changes to trigger cancer growth. Finally, researchers will use these findings to investigate new therapeutic strategies.

The research builds on past work by Lieberman’s lab, which has focused on developing small molecule inhibitors targeting EBV. He said the new project would focus on studying drugs that are already in development, and looking for ways to make them more targeted or use them in combination with other therapies.

Tempera said the group’s integrated approach sets it apart.“Our project will study both metabolic and epigenetic vulnerabilities simultaneously,” he said. “Combining these two aspects can provide a comprehensive understanding of the role of EBV infection in cancer and its underlying mechanisms, leading to unique insights and therapeutic opportunities.”

Co-authors: Ben Gewurz of Harvard; Joseph Salvino, Samantha Soldan, Andrew Kossenkov, Louise Showe, and Qin Liu of Wistar.

Darien Sutton
The Wistar Institute
215-870-2048
dsutton@wistar.org

GlobeNewswire Distribution ID 8881269

Hitachi Energy selected as preferred technology provider for the longest HVDC link in the UK

HVDC interconnection to secure power transmission and support new renewable electricity generation with the country’s largest electricity transmission project

Zurich, Switzerland, July 26, 2023 (GLOBE NEWSWIRE) — Hitachi Energy, a global technology leader that is advancing a sustainable energy future for all, today announced it has been selected as preferred technology provider of SSEN Transmission and National Grid, to supply two high-voltage direct current (HVDC) converter stations to interconnect the Scottish and English power grids.

The energy transition requires a collaborative effort that can only be achieved with advanced technologies and new ways of working. In appointing Hitachi Energy as their preferred technology provider, SSEN Transmission and National Grid secure best-in-class technology and future production capacity in a rapidly growing market. For Hitachi Energy, this enables investment in new production capacity and to undertake large-scale recruitment drives. It also strengthens collaboration, standardization of solutions, and synergies between projects.

The integration of renewables requires solutions that make the grid resilient, stable, and flexible. Hitachi Energy’s innovation and long development of voltage sourced converter (VSC) power electronics and control and protection (MACH™) technologies meet the requirements alongside many other landmark grid integration projects.

Eastern Green Link 2 will consist of two 525-kilovolt (kV) bipole VSC converter stations connected by 440 kilometers of subsea cable and 70 kilometers of underground cable, making it the longest HVDC link in the UK. The link will efficiently supply a total of 2,000 megawatts (MW) of electricity, which is enough to power around two million UK homes.1

The link will help to secure power transmission in the northern UK and support the integration of new renewable electricity generation in Scotland, as part of the UK’s Net Zero Strategy.2 As much as 11,000 MW of offshore wind capacity is possible in Scottish waters by 20303, and HVDC transmission will play a large part in bringing this vast amount of renewable power to shore and south, to communities across the country.

“The UK’s Net Zero Strategy has ambitious targets which will require vast amounts of new renewable generation. Electricity will be the backbone of the entire energy system,” said Niklas Persson, Managing Director at Hitachi Energy’s Grid Integration business. “Our pioneering HVDC technology will ensure that this electricity will reliably and efficiently get where it’s needed most.”

“This is another important milestone for EGL2 which is part of the new network infrastructure required to help the UK meet its net zero and energy security ambitions,” said Sarah Sale, Deputy Project Director of National Grid. “Along with cabling bidder and formal joint venture announcements, this is another key part of the project which is now in place and ready for the delivery phase. We look forward to working in collaboration with Hitachi Energy and BAM as the project continues to progress.”

“The converter stations at either end of the cable will play a crucial role in making the power transported subsea suitable for transportation around the onshore transmission network – getting Hitachi Energy and BAM in place to deliver that technology is great for the project,” said Ricky Saez, the EGL2 Project Director from SSEN Transmission.

“BAM is delighted to work in collaboration with Hitachi Energy on this vital renewable energy project for National Grid and SSEN Transmission,” said Huw Jones, Executive Director of BAM Nuttall. “The converter stations will enable the transmission of green energy from areas of offshore wind generation to centers of population, supporting the UK’s net zero ambitions and providing better energy security. We look forward to engaging with local communities and suppliers in Aberdeenshire and North Yorkshire, supporting BAM’s vision to deliver sustainable infrastructure for our clients, stakeholders, and the communities in which we work.”

Hitachi Energy is collaborating with BAM, a construction company that designs, builds, and maintains sustainable buildings and infrastructure, to provide the civil and installation scope for the project. The collaboration with BAM will leverage the core competencies of the two companies to deliver a best-in-class solution for the project.

Hitachi Energy pioneered commercial HVDC technology almost 70 years ago and has delivered more than half of the world’s HVDC projects.

1 https://www.nationalgrid.com/electricity-transmission/network-and-infrastructure/segl2
2 https://www.gov.uk/government/publications/net-zero-strategy
3 https://www.gov.scot/publications/offshore-wind-policy-statement/
4 Modular Advanced Control for HVDC (MACH™)

HVDC website:

https://www.hitachienergy.com/offering/product-and-system/hvdc

Photo captions:

North Sea Link Blyth Converter Station UK

Eastern Green Link 2

About Hitachi Energy
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world’s energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 40,000 people in 90 countries and generate business volumes of over $10 billion USD.
https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachments

Jocelyn Chang
Hitachi Energy
jocelyn.chang@hitachienergy.com

GlobeNewswire Distribution ID 8881044

Curia étend ses capacités dans le domaine des produits biologiques en accédant à l’ADN doggybone de Touchlight

Curia collabore avec Touchlight afin d’élargir son offre de fabrication d’ARNm pour permettre l’accès à l’ADN enzymatique doggybone (dbDNA™)

ALBANY, New York, et Hampton, Royaume-Uni, 25 juill. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan dans le domaine de la recherche, du développement et de la fabrication en sous-traitance, et Touchlight, une société pionnière dans la production enzymatique d’ADN, ont annoncé aujourd’hui un accord qui fournira à Curia ainsi qu’à ses clients un moyen simplifié d’accès à l’ADN doggybone de Touchlight (dbDNA). L’arrangement étend les offres de fabrication d’ARNm de Curia avec une source supplémentaire et différenciée de matière première d’ADN qui est immédiatement accessible par les clients de Curia. Dans le cadre de l’accord, Touchlight fabriquera directement dbDNA pour le compte des clients de Curia.

« Curia reste déterminée à renforcer ses offres de produits biologiques et ses capacités de fabrication d’ARNm de bout en bout », a déclaré Christopher Conway, président de la R&D chez Curia. « Avec l’ajout de l’ADN enzymatique grâce à notre partenariat avec Touchlight, nos clients bénéficieront d’un avantage décisif en termes d’évolutivité et de rapidité de commercialisation. »

dbDNA de Touchlight est un vecteur d’ADN linéaire, à double brin, fermé de manière covalente. L’ADN sert de modèle pour l’élaboration des traitements à base d’ARNm. Grâce à un processus enzymatique simple appelé transcription in vitro, les informations génétiques sont copiées de l’ADN à l’ARNm. Cet ARNm est alors capable d’apprendre aux cellules à fabriquer des protéines spécifiques qui sont utilisées pour soigner ou prévenir des maladies. L’ADN enzymatique de Touchlight est produit par un processus enzymatique acellulaire qui offre des avantages inégalés en termes de rapidité, de qualité et de capacité par rapport à la production traditionnelle d’ADN plasmidique.

Karen Fallen, PDG de Touchlight, a commenté : « Nous sommes ravis de travailler avec Curia afin d’élargir l’accès à dbDNA en tant que matière de départ essentielle. Travailler en parallèle avec d’autres CDMO est un élément clé de notre volonté de permettre un large accès du marché à dbDNA. Curia met en place une solution complète pour l’ARNm, et cet accord permet aux deux entreprises d’étendre leur offre à un public plus large. »

dbDNA de Touchlight est une solution nouvelle, largement applicable et polyvalente, qui permet à Curia de renforcer ses capacités de fabrication d’ARNm en complément de son offre de plasmides de qualité bioprocédurale.

À propos de Curia

Curia est une une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

À propos de Touchlight

Touchlight est une CDMO privée basée à Londres, au Royaume-Uni, qui se concentre sur la prestation de services d’ADN et la fabrication d’ADN doggybone (dbDNA™) produit de manière enzymatique pour permettre le développement de médicaments génétiques. Touchlight assure le développement et la fabrication rapides et enzymatiques d’ADN pour la production de tous les traitements avancés, comprenant l’ARNm, la thérapie génique virale et non virale, et l’API d’ADN. dbDNA est une structure minimale, linéaire et fermée de façon covalente, qui élimine les séquences bactériennes. La plateforme révolutionnaire de production enzymatique de Touchlight permet une vitesse et une échelle sans précédent, et offre la possibilité de cibler des gènes d’une taille et d’une complexité impossibles à atteindre avec les technologies actuelles. Les clients peuvent bénéficier d’une assistance depuis la phase préclinique jusqu’à l’octroi de licence et au transfert de technologie pour une utilisation en interne, en passant par le développement et l’approvisionnement.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contact chez Touchlight :

Karen Fallen, présidente-directrice générale
Robin Bodicoat, directeur du marketing
E : info@touchlight.com
T : +44 20 8481 9200

GlobeNewswire Distribution ID 8880042

Curia expande sua capacidade biológica com acesso ao DNA doggybone da Touchlight

Curia colabora com a Touchlight para expandir sua oferta de produção de mRNA para permitir o acesso ao DNA enzimático de doggybone (dbDNA™)

ALBANY, N.Y. e HAMPTON, Reino Unido, July 25, 2023 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratação de pesquisa, desenvolvimento e fabricação, e a Touchlight, uma empresa pioneira na produção de DNA enzimático, anunciou hoje um acordo de fornecimento para a Curia e seus clientes de um acesso arrojado ao DNA doggybone (dbDNA) da Touchlight. O acordo expande as ofertas de produção de mRNA da Curia com uma fonte adicional diferenciada de matéria-prima de DNA imediatamente disponível para ser acessada pelos clientes da Curia. Sob o acordo, a Touchlight passará a produzir o dbDNA diretamente em nome dos clientes da Curia.

“A Curia continua empenhada a aprimorar nossas ofertas biológicas e capacidade de manufatura completa de mRNA”, disse Christopher Conway, presidente de P&D da Curia. “Com a adição do DNA enzimático por meio da nossa parceria com a Touchlight, nossos clientes terão uma vantagem essencial em termos de escalabilidade e velocidade no mercado.”

O dbDNA da Touchlight é um vetor de DNA linear, de fita dupla e fechado covalentemente. O DNA serve como modelo para terapias de mRNA. Através de um processo enzimático simples chamado transcrição in vitro, a informação genética é copiada do DNA para o mRNA. Este mRNA é então capaz de ensinar as células a produzir proteínas precisas que são usadas para tratar ou prevenir doenças. O DNA enzimático da Touchlight é produzido com um processo enzimático livre de células que oferece benefícios incomparáveis em velocidade, qualidade e capacidade quando comparado à produção tradicional de DNA de plasmídeo.

Karen Fallen, CEO da Touchlight, comentou: “É um grande prazer trabalhar com a Curia na maior expansão do acesso ao dbDNA como um material inicial essencial. O trabalho junto aos outros CDMOs é um componente essencial do nosso foco em permitir amplo acesso ao mercado de dbDNA. A Curia está criando uma solução abrangente de mRNA, e esse acordo permite que ambas as empresas ampliem sua oferta para um público mais amplo.”

O dbDNA da Touchlight é uma nova solução amplamente aplicável e versátil, avançando a capacidade de produção de mRNA da Curia como um complemento à sua oferta de plasmídeo de grau de bioprocessamento.

Sobre a Curia

A Curia é uma organização líder em contratos de pesquisa, desenvolvimento e fabricação que fornece produtos e serviços de P&D por meio da fabricação comercial para clientes farmacêuticos e biofarmacêuticos. Os quase 4.000 funcionários da Curia em 29 locais nos EUA, Europa e Ásia ajudam seus clientes a avançar da curiosidade para a cura. Saiba mais em CuriaGlobal.com.

Sobre a Touchlight

A Touchlight é uma CDMO de propriedade privada com sede em Londres, Reino Unido, focada no fornecimento de serviços de DNA e na fabricação de produtos enzimáticos doggybone DNA (dbDNA™) para permitir o desenvolvimento de medicamentos genéticos. A Touchlight fornece desenvolvimento e fabricação rápidos e enzimáticos de DNA para toda a produção de terapia avançada, incluindo mRNA, terapia gênica viral e não viral e API de DNA. O dbDNA é uma estrutura mínima, linear e covalentemente fechada, que elimina sequências bacterianas. A revolucionária plataforma de produção enzimática da Touchlight permite velocidade, escala e capacidade sem precedentes para o direcionamento de genes com um tamanho e complexidade impossíveis com as tecnologias atuais. Os clientes podem ser apoiados durante a fase pré-clínica, desenvolvimento e fornecimento, até o licenciamento e transferência de tecnologia para uso interno.

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contato da Touchlight:

Karen Fallen, Diretora Executiva
Robin Bodicoat, Diretor de Marketing
E: info@touchlight.com
T: +44 (20) 8481 9200

GlobeNewswire Distribution ID 8880042

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)

ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA). The arrangement expands Curia’s mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.

“Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities,” said Christopher Conway, President of R&D, Curia. “With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market.”

Touchlight’s dbDNA is a linear, double-stranded, covalently-closed DNA vector. DNA serves as the template for making mRNA therapies. Through a simple enzymatic process called in vitro transcription, genetic information is copied from DNA to mRNA. This mRNA is then able to teach the cells to make precise proteins that are used to treat or prevent diseases. Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

Karen Fallen, CEO, Touchlight commented: “We are delighted to work with Curia in order to further expand access to dbDNA as a critical starting material. Working in parallel with fellow CDMOs is a key component of our focus upon enabling broad market access to dbDNA. Curia is building a comprehensive mRNA solution, and this arrangement enables both companies to extend their offering to a wider audience.”

Touchlight’s dbDNA is a novel solution that is widely applicable and versatile, advancing Curia’s mRNA manufacturing capabilities as a complement to its bioprocessing-grade plasmid offering.

About Curia

Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on providing DNA services and manufacturing enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy, and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply to licensing and tech transfer for use in-house.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Touchlight contact information:

Karen Fallen, Chief Executive Officer
Robin Bodicoat, Head of Marketing
E: info@touchlight.com
T: +44 20 8481 9200

GlobeNewswire Distribution ID 8879177